Singapore infrastructure a draw for pharma giants
Pharmaceutical firm AbbVie has invested S$400 million to open a manufacturing plant at Tuas Biomedical Park, to support its global manufacturing pipeline.
IN 50 YEARS, Singapore has undergone significant transformation from a developing country into a thriving metropolis. Today, with its robust physical and regulatory environment, global connectivity and skilled talent pool, this city-state is a multidisciplinary hub for businesses looking to access emerging market opportunities across the region.
The nation's strong foundation in research and development (R&D) has drawn significant investments from research institutes and biopharmaceutical companies. In the span of a decade from 2005 to 2015, we have seen a 30 per cent increase in the number of clinical research programmes conducted in Singapore.
As more companies embark on drug discovery and translational clinical research in Singapore, the implications on its manufacturing output cannot be overlooked. Today, six out of the top 10 drugs globally are made in Singapore.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Columns
‘Competition for talent’ a poor excuse to keep key executives’ pay under wraps
OCBC should put its properties into a Reit and distribute the trust’s units to shareholders
Why a stronger US dollar is dangerous
An overstimulated US economy is asking for trouble
Too many property agents? Cap commissions on home sales
Time to study broadening of private market access